{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-058242","form_type":"8-K","ticker":"ATOS","cik":"0001488039","company_name":"ATOSSA THERAPEUTICS, INC.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.627142+00:00","generated_at":"2026-06-02T02:12:16.664313+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Atossa Q1 2024 net loss $5.9M; EVANGELINE 100% disease control at 24 weeks","bullets":["Net loss of $5.9M (operating expenses $7.0M, interest income $1.1M); cash $84.0M, no debt.","EVANGELINE study: 100% disease control rate, 37% avg lesion size reduction, 92% Ki-67 drop at 24 weeks.","Initiated combination study of (Z)-endoxifen + abemaciclib in ER+/HER2- breast cancer (20 patients).","I-SPY 2 Phase 2 trial fully enrolled; data readout expected in H2 2024.","Appointed medical oncologist Dr. Tessa Cigler to Board of Directors."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-058242","json":"https://secwatch.observer/filing/0000950170-24-058242.json","markdown":"https://secwatch.observer/filing/0000950170-24-058242.md","text":"https://secwatch.observer/filing/0000950170-24-058242.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1488039/000095017024058242/0000950170-24-058242-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1488039/000095017024058242/atos-20240513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T02:12:16.664313+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"da7bd24ec96fd2a9de5d5527f72431691dd08739","claim":"ATOSSA THERAPEUTICS, INC. reported financial results for fiscal quarter ended March 31, 2024.","evidence_excerpt":"On May 13, 2024, Atossa Therapeutics, Inc. (the “Company”) issued a press release announcing the quarter ended March 31, 2024 financial results and providing a Company update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1488039/000095017024058242/0000950170-24-058242-index.htm","confidence":0.4,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}